Combination chemotherapy must strike a difficult balance between safety and efficacy. Current regimens suffer from poor therapeutic impact because drugs are given at their maximum tolerated dose (MTD), which compounds the toxicity risk and exposes tumors to non‐optimal drug ratios. A modular framework has been developed that selectively delivers drug combinations at synergistic ratios via tumor‐targeting aptamers for effective low‐dose treatment. A nucleolin‐recognizing aptamer was coupled to peptide scaffolds laden with precise ratios of doxorubicin (DOX) and camptothecin (CPT). This construct had an extremely low IC50(31.9 n
Designing multi‐drug regimens often involves target‐ and synergy prediction‐based drug selection, and subsequent dose escalation to achieve the maximum tolerated dose (MTD) of each drug. This approach may improve efficacy, but not the optimal efficacy and often substantially increases toxicity. Drug interactions depend on many pathways in the omics networks and further complicate the design process. The virtually infinite drug–dose parameter space cannot be reconciled using conventional approaches, which are largely based on prediction. This barrier at least partially accounts for the low response rates that are observed with conventional mono‐ and combinatorial chemotherapy. A combination of nonstandard therapies for colorectal cancer (AGCH: adriamycin, gemcitabine, cisplatin, and herceptin) at ¼ MTD is used to treat the rats, the tumor response rates varied in a wide range. Some of the tumor response rates are close to that of control group. This work harnesses an artificial intelligence (AI) platform that is mechanism free and can dynamically optimize combinatorial therapy in rats. The individually optimized AGCH regimen reveal starkly different drug–dose parameters, which can converge each rat toward the same and low tumor response rate. Importantly, this AI‐based drug–dose optimization technology is an actionable platform, which can achieve N‐of‐1 therapy.
more » « less- PAR ID:
- 10373085
- Publisher / Repository:
- Wiley Blackwell (John Wiley & Sons)
- Date Published:
- Journal Name:
- Advanced Therapeutics
- Volume:
- 3
- Issue:
- 4
- ISSN:
- 2366-3987
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
more » « less
Abstract m ) against MDA‐MB‐231 breast cancer cells in vitro, and exhibited in vivo efficacy at micro‐dose injections (500 and 350 μg kg−1 dose−1of DOX and CPT, respectively) that are 20–30‐fold lower than their previously‐reported MTDs. This approach represents a generalizable strategy for the safe and consistent delivery of combination drugs in oncology. -
more » « less
Abstract Combination chemotherapy must strike a difficult balance between safety and efficacy. Current regimens suffer from poor therapeutic impact because drugs are given at their maximum tolerated dose (MTD), which compounds the toxicity risk and exposes tumors to non‐optimal drug ratios. A modular framework has been developed that selectively delivers drug combinations at synergistic ratios via tumor‐targeting aptamers for effective low‐dose treatment. A nucleolin‐recognizing aptamer was coupled to peptide scaffolds laden with precise ratios of doxorubicin (DOX) and camptothecin (CPT). This construct had an extremely low IC50(31.9 n
m ) against MDA‐MB‐231 breast cancer cells in vitro, and exhibited in vivo efficacy at micro‐dose injections (500 and 350 μg kg−1 dose−1of DOX and CPT, respectively) that are 20–30‐fold lower than their previously‐reported MTDs. This approach represents a generalizable strategy for the safe and consistent delivery of combination drugs in oncology. -
more » « less
Abstract Drug resistance poses a crucial challenge in healthcare, with response rates to chemotherapy and targeted therapy remaining low. Individual patient's resistance is exacerbated by the intricate heterogeneity of tumor cells, presenting significant obstacles to effective treatment. To address this challenge, DrugFormer, a novel graph‐augmented large language model designed to predict drug resistance at single‐cell level is proposed. DrugFormer integrates both serialized gene tokens and gene‐based knowledge graphs for the accurate predictions of drug response. After training on comprehensive single‐cell data with drug response information, DrugFormer model presents outperformance, with higher F1, precision, and recall in predicting drug response. Based on the scRNA‐seq data from refractory multiple myeloma (MM) and acute myeloid leukemia (AML) patients, DrugFormer demonstrates high efficacy in identifying resistant cells and uncovering underlying molecular mechanisms. Through pseudotime trajectory analysisunique drug‐resistant cellular states associated with poor patient outcomes are revealed. Furthermore, DrugFormer identifies potential therapeutic targets, such as COX8A, for overcoming drug resistance across different cancer types. In conclusion, DrugFormer represents a significant advancement in the field of drug resistance prediction, offering a powerful tool for unraveling the heterogeneity of cellular response to drugs and guiding personalized treatment strategies.
-
more » « less
Abstract Drug development is often hindered by the failure of preclinical models to accurately assess and predict the efficacy and safety of drug candidates. Body‐on‐a‐chip (BOC) microfluidic devices, a subset of microphysiological systems (MPS), are being created to better predict human responses to drugs. Each BOC is designed with separate organ chambers interconnected with microfluidic channels mimicking blood recirculation. Here, we describe the design of the first pumpless, unidirectional, multiorgan system and apply this design concept for testing anticancer drug treatments. HCT‐116 colon cancer spheroids, HepG2/C3A hepatocytes, and HL‐60 promyeloblasts were embedded in collagen hydrogels and cultured within compartments representing “colon tumor”, “liver,” and “bone marrow” tissue, respectively. Operating on a pumpless platform, the microfluidic channel design provides unidirectional perfusion at physiologically realistic ratios to multiple channels simultaneously. The metabolism‐dependent toxic effect of Tegafur, an oral prodrug of 5‐fluorouracil, combined with uracil was examined in each cell type. Tegafur‐uracil treatment induced substantial cell death in HCT‐116 cells and this cytotoxic response was reduced for multicellular spheroids compared to single cells, likely due to diffusion‐limited drug penetration. Additionally, off‐target toxicity was detected by HL‐60 cells, which demonstrate that such systems can provide useful information on dose‐limiting side effects. Collectively, this microscale cell culture analog is a valuable physiologically‐based pharmacokinetic drug screening platform that may be used to support cancer drug development.
-
more » « less
Abstract While systemic immuno‐oncology therapies have shown remarkable success, only a limited subset of patients benefit from them. The Click Activated Protodrugs Against Cancer (CAPAC) platform is a click chemistry‐based approach that activates cancer drugs at a specific tumor with minimal systemic toxicity. The CAPAC Platform is agnostic to tumor characteristics that can vary across patients and hence applicable to several types of tumors. The benefits of SQ3370 (lead candidate of CAPAC) are described to achieve systemic anti‐tumor responses in mice bearing two tumors. SQ3370 consists of a biopolymer, injected in a single lesion, followed by systemic doses of an attenuated protodrug of doxorubicin (Dox). SQ3370 is well‐tolerated at 5.9‐times the maximum dose of conventional Dox, increased survival by 63% and induces a systemic anti‐tumor response against injected and non‐injected lesions. The sustained anti‐tumor response also correlates with immune activation measured at both lesions. SQ3370 can potentially benefit patients with micro‐metastatic lesions.
